Biotech Capital Is Clustering Around Fewer, Bigger Bets

Biotech funding is undergoing a profound shift. In the first quarter of 2025, nearly eighty percent of the $4.1 billion tracked by BiopharmaDive across venture financing rounds went to just thirteen megarounds—those exceeding $100 million each, according to BiopharmaDive data published on April 3, 2025. These high-value investments reflect a recurring theme: institutional investors aren’t spreading capital broadly among high-risk startups. Instead, they are backing fewer companies, choosing size and focus over experimentation.

“Jack Bannister, senior managing director at Leerink Partners, said, "The growth in round sizes is indicative of a trade-off venture firms appear more willing to make in the current climate. In joining bigger syndicates, investors dilute their ownership stake, but the companies they're backing have a better chance to survive, grow and 'not immediately return to financing mode.'"

While large funding rounds in biotech aren’t new, their growing frequency reflects structural changes in how venture capital operates within the sector. Data from 2024 underscores the scale of the trend: venture firms participated in 72 megarounds that year—an increase from 42 such deals in 2023, according to BiopharmaDive's April 2025 report. According to BiopharmaDive data, the median round size for the latter half of 2024 consistently eclipsed $100 million, a figure that now appears to be the floor for competitive financing rounds targeting later-stage development programs.

“There’s a bit of a flight to quality happening,” said Srini Akkaraju, founder and managing general partner at Samsara BioCapital. Investors are increasingly seeking initiatives that build on scientific work with clear clinical-stage readiness or proven therapeutic promise. According to Akkaraju, some programs, including those developed abroad, offer a way to “skip all of this—four years of toiling away to get to a drug and prove that it does something in humans.” This ability to start with advanced-stage assets reduces discovery timelines, creating shorter paths toward return on investment.

This dynamic also reveals changing priorities. Unlike the high-experimentation environment of past funding cycles, recent biotech investments show a preference for later-stage companies, particularly those with established science platforms or differentiated therapeutic approaches geared toward high-value diseases such as obesity, oncology, and rare genetic disorders. Among Q1 2025’s marquee rounds was Verdiva Bio’s $411 million Series A for an obesity treatment program, as reported by BiopharmaDive. On the AI side of drug discovery, Isomorphic Labs secured a staggering $600 million, marking the largest deal of the quarter.

While the pivot to bigger bets may indicate confidence in select ventures, it also highlights a wider climate of financial caution. According to Bannister, later-stage investments in well-capitalized startups allow companies to “wait out the IPO market,” which remains bearish for biotech. Raising substantial private funds shields these firms from the downside of a lackluster debut while maintaining higher valuations. This appears essential at a time when public offerings are no longer a guaranteed liquidity event for early investors.

The consolidation trend also signals a shift in venture behavior that some observers associate more with private equity than traditional venture capital. “Venture investors are also ‘increasingly behaving like private equity firms,’ searching for safer bets and quicker investment returns,” said John Wu, managing director and partner at Boston Consulting Group. In practice, this may translate into fewer exploratory programs, as smaller biotech startups struggle to secure funding against their more advanced, better-capitalized competitors.

The ramifications extend beyond the companies directly affected. As venture firms reduce their exposure to early-stage, high-risk projects, opportunities for scientific breakthroughs—whether in unproven technology platforms or novel therapeutic modalities—may decline. The clustering of biotech capital around fewer, more “safe” bets mirrors an industry navigating uncertainty, a dynamic shaped as much by market forces as by the longer timelines required to demonstrate clinical and commercial viability.

For institutional players, this measured approach may reflect strategic conservatism amidst a prolonged period of financial volatility. “Everybody’s hurting,” Akkaraju noted, suggesting that bearish market sentiment will likely persist in the near term. Nevertheless, consolidation around large-scale financing rounds doesn’t necessarily diminish the industry’s long-term potential. Instead, it prioritizes stability and incremental progress over breadth—a pragmatic recalibration for an era where venture capital alone cannot sustain unbridled experimentation.

Still, questions remain about whether this approach can sustain the biotech innovation ecosystem in the long run. As Bannister noted, the industry's preference for megarounds may help individual companies survive but could create bottlenecks for transformative ideas in earlier stages of development. The real concern is whether this trend, defined by fewer but larger investments, reinforces existing scientific capabilities or limits the diversity of ideas that reach clinical pipelines.

While the trajectory of biotech capital suggests growing maturity, it also poses challenges for startups vying to disrupt the system. Investors may ultimately need to decide whether a more experimental, diversified approach remains justifiable, even at the expense of short-term predictability.